Do analysts rate ZSQR or PRQR?

ProQR Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 310.83%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Coeptis Therapeutics. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Coeptis Therapeutics 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 ProQR Therapeutics 1 Sell rating(s) 1 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.57

Does the media prefer ZSQR or PRQR?

In the previous week, ProQR Therapeutics had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 6 mentions for ProQR Therapeutics and 4 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.29 beat ProQR Therapeutics' score of 0.25 indicating that Coeptis Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Coeptis Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PRQR or ZVRA?

In the previous week, ProQR Therapeutics had 3 more articles in the media than Zevra Therapeutics. MarketBeat recorded 6 mentions for ProQR Therapeutics and 3 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.63 beat ProQR Therapeutics' score of 0.25 indicating that Zevra Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Zevra Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor PRQR or CYRX?

In the previous week, ProQR Therapeutics had 1 more articles in the media than CryoPort. MarketBeat recorded 6 mentions for ProQR Therapeutics and 5 mentions for CryoPort. CryoPort's average media sentiment score of 1.03 beat ProQR Therapeutics' score of 0.25 indicating that CryoPort is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral CryoPort 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has preferable earnings and valuation, IVA or PRQR?

ProQR Therapeutics has higher revenue and earnings than Inventiva. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Inventiva $5.07M 142.37 -$400.67M N/A N/A ProQR Therapeutics $17.99M 10.45 -$47.73M -$0.50 N/A

Does the media refer more to IVA or PRQR?

In the previous week, ProQR Therapeutics had 4 more articles in the media than Inventiva. MarketBeat recorded 6 mentions for ProQR Therapeutics and 2 mentions for Inventiva. Inventiva's average media sentiment score of 0.94 beat ProQR Therapeutics' score of 0.25 indicating that Inventiva is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Inventiva 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ALLO or PRQR?

In the previous week, ProQR Therapeutics had 4 more articles in the media than Allogene Therapeutics. MarketBeat recorded 6 mentions for ProQR Therapeutics and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.87 beat ProQR Therapeutics' score of 0.25 indicating that Allogene Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Allogene Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive ProQR Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

ProQR Therapeutics (PRQR) Competitors

$1.78 +0.26 (+16.67%)

As of 11:58 AM Eastern

Compare

PRQR vs. ZSQR, ZVRA, CYRX, IVA, and ALLO

Should you buy ProQR Therapeutics stock or one of its competitors? MarketBeat compares ProQR Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with ProQR Therapeutics include Coeptis Therapeutics (ZSQR), Zevra Therapeutics (ZVRA), CryoPort (CYRX), Inventiva (IVA), and Allogene Therapeutics (ALLO). These companies are all part of the "pharmaceutical products" industry.

How does ProQR Therapeutics compare to Coeptis Therapeutics?

Coeptis Therapeutics (NASDAQ:ZSQR) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, profitability, dividends, institutional ownership, media sentiment, risk and earnings.

13.9% of Coeptis Therapeutics shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 24.3% of Coeptis Therapeutics shares are held by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, ProQR Therapeutics had 2 more articles in the media than Coeptis Therapeutics. MarketBeat recorded 6 mentions for ProQR Therapeutics and 4 mentions for Coeptis Therapeutics. Coeptis Therapeutics' average media sentiment score of 0.29 beat ProQR Therapeutics' score of 0.25 indicating that Coeptis Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Coeptis Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ProQR Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ProQR Therapeutics has a net margin of -331.33% compared to Coeptis Therapeutics' net margin of -810.04%. ProQR Therapeutics' return on equity of -84.87% beat Coeptis Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Coeptis Therapeutics	-810.04%	-92.29%	-73.52%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

Coeptis Therapeutics has higher earnings, but lower revenue than ProQR Therapeutics. Coeptis Therapeutics is trading at a lower price-to-earnings ratio than ProQR Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Coeptis Therapeutics	$1.36M	463.63	-$11.92M	-$2.52	N/A
ProQR Therapeutics	$17.99M	10.45	-$47.73M	-$0.50	N/A

ProQR Therapeutics has a consensus target price of $7.33, suggesting a potential upside of 310.83%. Given ProQR Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than Coeptis Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Coeptis Therapeutics	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Coeptis Therapeutics has a beta of -0.22, meaning that its stock price is 122% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market.

Summary

ProQR Therapeutics beats Coeptis Therapeutics on 12 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Zevra Therapeutics?

ProQR Therapeutics (NASDAQ:PRQR) and Zevra Therapeutics (NASDAQ:ZVRA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, profitability, risk, institutional ownership, dividends, media sentiment, valuation and earnings.

ProQR Therapeutics has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market. Comparatively, Zevra Therapeutics has a beta of 0.91, meaning that its stock price is 9% less volatile than the broader market.

Zevra Therapeutics has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Zevra Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.45	-$47.73M	-$0.50	N/A
Zevra Therapeutics	$106.47M	7.68	$83.23M	$1.99	6.95

32.7% of ProQR Therapeutics shares are held by institutional investors. Comparatively, 35.0% of Zevra Therapeutics shares are held by institutional investors. 8.4% of ProQR Therapeutics shares are held by company insiders. Comparatively, 2.4% of Zevra Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, ProQR Therapeutics had 3 more articles in the media than Zevra Therapeutics. MarketBeat recorded 6 mentions for ProQR Therapeutics and 3 mentions for Zevra Therapeutics. Zevra Therapeutics' average media sentiment score of 0.63 beat ProQR Therapeutics' score of 0.25 indicating that Zevra Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Zevra Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ProQR Therapeutics presently has a consensus target price of $7.33, suggesting a potential upside of 310.83%. Zevra Therapeutics has a consensus target price of $29.29, suggesting a potential upside of 111.68%. Given ProQR Therapeutics' higher possible upside, research analysts clearly believe ProQR Therapeutics is more favorable than Zevra Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Zevra Therapeutics	0 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.82

Zevra Therapeutics has a net margin of 101.58% compared to ProQR Therapeutics' net margin of -331.33%. Zevra Therapeutics' return on equity of 51.49% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
Zevra Therapeutics	101.58%	51.49%	28.86%

Summary

Zevra Therapeutics beats ProQR Therapeutics on 12 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to CryoPort?

ProQR Therapeutics (NASDAQ:PRQR) and CryoPort (NASDAQ:CYRX) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their analyst recommendations, earnings, risk, dividends, media sentiment, profitability, institutional ownership and valuation.

In the previous week, ProQR Therapeutics had 1 more articles in the media than CryoPort. MarketBeat recorded 6 mentions for ProQR Therapeutics and 5 mentions for CryoPort. CryoPort's average media sentiment score of 1.03 beat ProQR Therapeutics' score of 0.25 indicating that CryoPort is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ProQR Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
CryoPort	1 Very Positive mention(s)	2 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

ProQR Therapeutics has a beta of 0.07, indicating that its share price is 93% less volatile than the broader market. Comparatively, CryoPort has a beta of 1.9, indicating that its share price is 90% more volatile than the broader market.

CryoPort has higher revenue and earnings than ProQR Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than CryoPort, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ProQR Therapeutics	$17.99M	10.45	-$47.73M	-$0.50	N/A
CryoPort	$182.94M	4.45	$78.30M	$1.35	11.97

CryoPort has a net margin of 41.57% compared to ProQR Therapeutics' net margin of -331.33%. CryoPort's return on equity of -7.92% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ProQR Therapeutics	-331.33%	-84.87%	-37.78%
CryoPort	41.57%	-7.92%	-4.79%

ProQR Therapeutics presently has a consensus price target of $7.33, indicating a potential upside of 310.83%. CryoPort has a consensus price target of $15.11, indicating a potential downside of 6.52%. Given ProQR Therapeutics' higher possible upside, analysts clearly believe ProQR Therapeutics is more favorable than CryoPort.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
CryoPort	0 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.80

32.7% of ProQR Therapeutics shares are owned by institutional investors. Comparatively, 92.9% of CryoPort shares are owned by institutional investors. 8.4% of ProQR Therapeutics shares are owned by insiders. Comparatively, 10.0% of CryoPort shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

CryoPort beats ProQR Therapeutics on 13 of the 16 factors compared between the two stocks.

How does ProQR Therapeutics compare to Inventiva?

Inventiva (NASDAQ:IVA) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

ProQR Therapeutics has higher revenue and earnings than Inventiva.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Inventiva	$5.07M	142.37	-$400.67M	N/A	N/A
ProQR Therapeutics	$17.99M	10.45	-$47.73M	-$0.50	N/A

In the previous week, ProQR Therapeutics had 4 more articles in the media than Inventiva. MarketBeat recorded 6 mentions for ProQR Therapeutics and 2 mentions for Inventiva. Inventiva's average media sentiment score of 0.94 beat ProQR Therapeutics' score of 0.25 indicating that Inventiva is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Inventiva	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ProQR Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

19.1% of Inventiva shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 32.0% of Inventiva shares are held by insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Inventiva presently has a consensus target price of $16.56, indicating a potential upside of 376.42%. ProQR Therapeutics has a consensus target price of $7.33, indicating a potential upside of 310.83%. Given Inventiva's stronger consensus rating and higher probable upside, research analysts clearly believe Inventiva is more favorable than ProQR Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Inventiva	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	3 Strong Buy rating(s)	3.10
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Inventiva has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Inventiva's return on equity of 0.00% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Inventiva	N/A	N/A	N/A
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

Inventiva has a beta of 0.68, meaning that its share price is 32% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.07, meaning that its share price is 93% less volatile than the broader market.

Summary

Inventiva beats ProQR Therapeutics on 11 of the 15 factors compared between the two stocks.

How does ProQR Therapeutics compare to Allogene Therapeutics?

Allogene Therapeutics (NASDAQ:ALLO) and ProQR Therapeutics (NASDAQ:PRQR) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, media sentiment, profitability, earnings, dividends and risk.

Allogene Therapeutics has a beta of 0.46, meaning that its stock price is 54% less volatile than the broader market. Comparatively, ProQR Therapeutics has a beta of 0.07, meaning that its stock price is 93% less volatile than the broader market.

ProQR Therapeutics has higher revenue and earnings than Allogene Therapeutics. ProQR Therapeutics is trading at a lower price-to-earnings ratio than Allogene Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allogene Therapeutics	$20K	37,535.06	-$190.89M	-$0.77	N/A
ProQR Therapeutics	$17.99M	10.45	-$47.73M	-$0.50	N/A

Allogene Therapeutics has a net margin of 0.00% compared to ProQR Therapeutics' net margin of -331.33%. Allogene Therapeutics' return on equity of -56.45% beat ProQR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allogene Therapeutics	N/A	-56.45%	-40.36%
ProQR Therapeutics	-331.33%	-84.87%	-37.78%

83.6% of Allogene Therapeutics shares are held by institutional investors. Comparatively, 32.7% of ProQR Therapeutics shares are held by institutional investors. 13.2% of Allogene Therapeutics shares are held by company insiders. Comparatively, 8.4% of ProQR Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Allogene Therapeutics currently has a consensus price target of $8.52, suggesting a potential upside of 291.83%. ProQR Therapeutics has a consensus price target of $7.33, suggesting a potential upside of 310.83%. Given ProQR Therapeutics' higher probable upside, analysts clearly believe ProQR Therapeutics is more favorable than Allogene Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allogene Therapeutics	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.69
ProQR Therapeutics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, ProQR Therapeutics had 4 more articles in the media than Allogene Therapeutics. MarketBeat recorded 6 mentions for ProQR Therapeutics and 2 mentions for Allogene Therapeutics. Allogene Therapeutics' average media sentiment score of 1.87 beat ProQR Therapeutics' score of 0.25 indicating that Allogene Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Allogene Therapeutics	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
ProQR Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Allogene Therapeutics beats ProQR Therapeutics on 11 of the 17 factors compared between the two stocks.

Get ProQR Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PRQR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PRQR vs. The Competition

Export

Metric	ProQR Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$185.96M	$3.64B	$6.85B	$12.33B
Dividend Yield	N/A	2.22%	2.67%	6.11%
P/E Ratio	-3.53	21.42	25.86	24.20
Price / Sales	10.45	341.79	550.66	101.54
Price / Cash	N/A	62.10	29.09	36.93
Price / Book	3.37	8.44	10.89	6.42
Net Income	-$47.73M	$23.92M	$3.58B	$336.87M
7 Day Performance	-5.05%	2.92%	2.51%	0.94%
1 Month Performance	12.97%	0.52%	0.22%	-0.53%
1 Year Performance	-12.50%	66.92%	35.34%	27.96%

ProQR Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PRQR ProQR Therapeutics	2.9044 of 5 stars	$1.79 +16.7%	$7.33 +310.8%	-25.0%	$185.96M	$17.99M	N/A	180	Analyst Forecast
ZSQR Coeptis Therapeutics	0.1708 of 5 stars	$13.38 -9.0%	N/A	+60.2%	$756.56M	$1.36M	N/A	2	News Coverage Short Interest Increase High Trading Volume
ZVRA Zevra Therapeutics	4.4271 of 5 stars	$13.00 +2.8%	$29.29 +125.3%	+50.2%	$747.81M	$106.47M	6.53	20
CYRX CryoPort	3.8389 of 5 stars	$14.76 -0.1%	$15.11 +2.4%	+115.9%	$744.44M	$176.18M	10.93	1,186
IVA Inventiva	2.8037 of 5 stars	$3.71 +5.7%	$16.56 +346.2%	+12.5%	$729.05M	$4.48M	N/A	100	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PRQR) was last updated on 6/29/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

ProQR Therapeutics (PRQR) Competitors

PRQR vs. ZSQR, ZVRA, CYRX, IVA, and ALLO

How does ProQR Therapeutics compare to Coeptis Therapeutics?

Summary

How does ProQR Therapeutics compare to Zevra Therapeutics?

Summary

How does ProQR Therapeutics compare to CryoPort?

Summary

How does ProQR Therapeutics compare to Inventiva?

Summary

How does ProQR Therapeutics compare to Allogene Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

ProQR Therapeutics (PRQR) Competitors

PRQR vs. ZSQR, ZVRA, CYRX, IVA, and ALLO

How does ProQR Therapeutics compare to Coeptis Therapeutics?

Do institutionals & insiders have more ownership in ZSQR or PRQR?

Does the media prefer ZSQR or PRQR?

Is ZSQR or PRQR more profitable?

Which has stronger valuation and earnings, ZSQR or PRQR?

Do analysts rate ZSQR or PRQR?

Which has more risk & volatility, ZSQR or PRQR?

Summary

How does ProQR Therapeutics compare to Zevra Therapeutics?

Which has more volatility and risk, PRQR or ZVRA?

Which has higher valuation & earnings, PRQR or ZVRA?

Do insiders and institutionals have more ownership in PRQR or ZVRA?

Does the media favor PRQR or ZVRA?

Do analysts recommend PRQR or ZVRA?

Is PRQR or ZVRA more profitable?

Summary

How does ProQR Therapeutics compare to CryoPort?

Does the media favor PRQR or CYRX?

Which has more risk & volatility, PRQR or CYRX?

Which has stronger earnings & valuation, PRQR or CYRX?

Is PRQR or CYRX more profitable?

Do analysts prefer PRQR or CYRX?

Do insiders and institutionals hold more shares of PRQR or CYRX?

Summary

How does ProQR Therapeutics compare to Inventiva?

Which has preferable earnings and valuation, IVA or PRQR?

Does the media refer more to IVA or PRQR?

Do institutionals & insiders believe in IVA or PRQR?

Do analysts rate IVA or PRQR?

Is IVA or PRQR more profitable?

Which has more volatility & risk, IVA or PRQR?

Summary

How does ProQR Therapeutics compare to Allogene Therapeutics?

Which has more volatility and risk, ALLO or PRQR?

Which has stronger valuation & earnings, ALLO or PRQR?

Is ALLO or PRQR more profitable?

Do institutionals and insiders hold more shares of ALLO or PRQR?

Do analysts rate ALLO or PRQR?

Does the media prefer ALLO or PRQR?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRQR vs. The Competition

ProQR Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools